Komori
K Pharma (4896) · RiskRestated

Unexpected Adverse Reactions Associated with Pharmaceuticals and Regenerative Medicine Products

First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY20252024: 120242025: 120252026: 12026
Same theme, other companies
Health Damage from Pharmaceuticals and Product Liability RiskA theme 58 companies write about · 67 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.

36 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 58 companies compared. The sentences above are computed from all 58.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「The pharmaceuticals and regenerative medicine products handled in our iPS drug discovery and regenerative medicine research and development may cause unexpected adverse reactions and other events from the clinical-trial stage through and after commercialization.」

    The company reiterates the risk of unexpected adverse reactions from clinical trials through after commercialization.
  2. FY2024RestatedAnnual report

    「The pharmaceuticals and regenerative medicine products handled in our iPS drug discovery and regenerative medicine research and development may cause unexpected adverse reactions and other events from the clinical-trial stage through and after commercialization.」

    The company reiterates the risk of unexpected adverse reactions from clinical trials through after commercialization.
  3. FY2023First statedAnnual report

    「The pharmaceuticals and regenerative medicine products handled in our iPS drug discovery and regenerative medicine research and development may cause unexpected adverse reactions from the clinical-trial stage through and after commercialization.」

    The company identifies the occurrence of adverse reactions from clinical trials through post-commercialization and their potential impact on its reputation and performance as a risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for K Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Unexpected Adverse Reactions Associated with Pharmaceuticals and Regenerative Medicine Products | K Pharma,Inc. (4896) | Komori